SAB Biotherapeutics, Inc. (SABS) stock
SABSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$3.20+0.25 (+8.47%)
Close on Nov 18, 2026Market cap $291.16MP/E –Yield –
SAB Biotherapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
SAB Biotherapeutics's total debt was $0 at Dec 31, 2024. For fiscal 2024 it was $0. The highest annual figure on record is $541.64K in fiscal 2022.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | – |
| FY2023 | Dec 31, 2023 | $0 | -100.0% |
| FY2022 | Dec 31, 2022 | $541.64K | – |
| FY2021 | Dec 31, 2021 | $0 | -100.0% |
| FY2020 | Dec 31, 2020 | $172.04K | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | $0 | – |
| Q4 FY2023 | Dec 31, 2023 | $0 | – |
| Q4 FY2022 | Dec 31, 2022 | $541.64K | +214.8% |
| Q2 FY2022 | Jun 30, 2022 | $0 | – |
| Q1 FY2022 | Mar 31, 2022 | $0 | – |
| Q4 FY2021 | Dec 31, 2021 | $0 | – |
| Q4 FY2020 | Dec 31, 2020 | $172.04K | – |
See a number that looks wrong?